The three quarterly reports released by Fosun Pharma today showed that from January to September, the company’s total profit and net profit attributable to shareholders of listed companies were 757 million yuan and 609 million yuan, respectively, an increase of 119.35% and 114.74% over the same period of last year; the first three quarters The company achieved earnings per share of 0.49 yuan.
It is understood that the significant growth of Fosun Pharma in the first three quarters was mainly attributable to the rapid growth of the company's drug R&D and manufacturing operations during the reporting period, the continued high-speed growth of the company's investment in the performance of Sinopharm Holdings, and certain assets. Sinopharm, China’s largest drug distribution company, continued to grow at a rapid rate. The net profit growth in the first three quarters exceeded 80%, and the market’s leading edge further expanded.
In drug R&D and manufacturing, sales of Fosun Pharma's core companies Shinseiyuan, Yakyu Pharmaceutical, and Wanbang Pharmaceutical all achieved breakthrough growth, and the leading products continued to maintain their leading position in their respective market segments.
Our Telecommunication Tower are made from quality sheet through bending, forming, automatic welding and hot galvanization. We can reach one-run machining length of 14m and can bend sheet of thickness up to 45mm. We adopt advanced welding procedures, automatically weld main joints and reach rank-II welding quality.
Telecommunication Tower
Telecommunication Tower, Telecommunication Steel Tower, Telecom Steel Tower, Telecom Steel Mono Tower
Jiangsu Xinjinlei Steel Industry Co., Ltd. , https://www.steel-pole.com